Aquilo Capital Management LLC Buys Shares of 592,802 Xenon Pharmaceuticals Inc (XENE)

Aquilo Capital Management LLC acquired a new stake in Xenon Pharmaceuticals Inc (NASDAQ:XENE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 592,802 shares of the biopharmaceutical company’s stock, valued at approximately $7,825,000. Xenon Pharmaceuticals comprises approximately 3.3% of Aquilo Capital Management LLC’s portfolio, making the stock its 9th biggest position. Aquilo Capital Management LLC owned approximately 2.35% of Xenon Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in Xenon Pharmaceuticals in the 3rd quarter valued at $111,000. Trexquant Investment LP bought a new position in Xenon Pharmaceuticals in the 3rd quarter valued at $148,000. Bank of Montreal Can grew its position in Xenon Pharmaceuticals by 433.3% in the 3rd quarter. Bank of Montreal Can now owns 11,721 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 9,523 shares during the last quarter. Kovack Advisors Inc. bought a new position in Xenon Pharmaceuticals in the 2nd quarter valued at $113,000. Finally, OppenheimerFunds Inc. grew its position in Xenon Pharmaceuticals by 104.3% in the 2nd quarter. OppenheimerFunds Inc. now owns 22,481 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 11,476 shares during the last quarter. 60.76% of the stock is currently owned by institutional investors.

XENE has been the topic of several research analyst reports. BidaskClub raised Xenon Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 5th. Stifel Nicolaus upped their price objective on Xenon Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday, August 10th. Finally, Zacks Investment Research downgraded Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 11th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $14.33.

Shares of Xenon Pharmaceuticals stock opened at $8.43 on Friday. The company has a current ratio of 29.36, a quick ratio of 29.36 and a debt-to-equity ratio of 0.15. Xenon Pharmaceuticals Inc has a 52 week low of $2.30 and a 52 week high of $15.92.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.16). Sell-side analysts anticipate that Xenon Pharmaceuticals Inc will post -1.64 earnings per share for the current fiscal year.

WARNING: “Aquilo Capital Management LLC Buys Shares of 592,802 Xenon Pharmaceuticals Inc (XENE)” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2018/12/01/aquilo-capital-management-llc-buys-shares-of-592802-xenon-pharmaceuticals-inc-xene.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.

Featured Story: What is a capital gain?

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc (NASDAQ:XENE).

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit